Sujal Shah
2021
In 2021, Sujal Shah earned a total compensation of $2.2M as Chief Executive Officer at Cymabay Therapeutics, a 16% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $320,100 |
|---|---|
| Option Awards | $1,338,482 |
| Salary | $550,000 |
| Other | $3,773 |
| Total | $2,212,355 |
Shah received $1.3M in option awards, accounting for 61% of the total pay in 2021.
Shah also received $320.1K in non-equity incentive plan, $550K in salary and $3.8K in other compensation.
Rankings
In 2021, Sujal Shah's compensation ranked 5,663rd out of 12,405 executives tracked by ExecPay. In other words, Shah earned more than 54.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,663 out of 12,405 | 54th |
Division Manufacturing | 2,398 out of 5,494 | 56th |
Major group Chemicals And Allied Products | 1,043 out of 2,369 | 56th |
Industry group Drugs | 931 out of 2,090 | 56th |
Industry Pharmaceutical Preparations | 670 out of 1,537 | 56th |
Source: SEC filing on April 26, 2022.
Shah's colleagues
We found four more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2021.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019